Last 12 months
Inside the activity.
6 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2021 Filed Nov 10, 2021 22:15 UTC |
Zigdon Shoshana Yael10% owner
|
SaleCommon Stock | 50,000 | $1.13 | $56,500.00 |
DisclosureSEC source: 0001493152-21-027889 · ownership.xml · nonDerivative · entry 1 Zigdon Shoshana Yael · CIK 0001866707 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,450,000 Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:22 UTC |
Elmaliah OrenDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021621 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, $.001 par value per share · 30,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 30,000 options shall vest on November 26, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:32 UTC |
Pardo BillyChief Product Officer and COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 160,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021632 · ownership.xml · derivative · entry 2 Pardo Billy · CIK 0001686858 · Chief Product Officer and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 160,000 Underlying: Common Stock, $.001 par value per share · 160,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. F2 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:32 UTC |
Pardo BillyChief Product Officer and COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 130,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021632 · ownership.xml · derivative · entry 1 Pardo Billy · CIK 0001686858 · Chief Product Officer and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock, $.001 par value per share · 130,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:27 UTC |
Kles OrChief Financial Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 130,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021626 · ownership.xml · derivative · entry 1 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock, $.001 par value per share · 130,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:30 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 130,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021629 · ownership.xml · derivative · entry 2 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 130,000 Underlying: Common Stock, $.001 par value per share · 130,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. F2 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:30 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 160,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021629 · ownership.xml · derivative · entry 1 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock, $.001 par value per share · 160,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:34 UTC |
Turchinsky IliaChief Technology Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021634 · ownership.xml · derivative · entry 1 Turchinsky Ilia · CIK 0001774527 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock, $.001 par value per share · 55,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. The option vests and becomes exercisable as to one-quarter of the total shares on each of November 26, 2020, May 26, 2021, November 26, 2021, and May 26, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:24 UTC |
Kaufman ArikDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021624 · ownership.xml · derivative · entry 1 Kaufman Arik · CIK 0001713725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, $.001 par value per share · 30,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 30,000 options shall vest on November 26, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:19 UTC |
Branitzky OronDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001213900-20-021619 · ownership.xml · derivative · entry 1 Braniztky Oron · CIK 0001714993 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, $.001 par value per share · 30,000 shares Expires 2025-08-10 F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which no options have vested to date. All 30,000 options shall vest on November 26, 2020. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 1,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 6 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock, $.001 par value per share · 1,000 shares Expires 2025-05-29 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 1,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 5 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 1,000 shares Expires 2024-05-29 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 4 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2024-09-06 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $13.65 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 3 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2023-09-06 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 2 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:57 UTC |
Elmaliah OrenDirector
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 667 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014430 · ownership.xml · derivative · entry 1 Elmaliah Oren · CIK 0001713701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 667 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which all options have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 33,334 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 12 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,334 Underlying: Common Stock, $.001 par value per share · 33,334 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 33,334 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 11 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 33,334 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 6,667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 10 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,667 Underlying: Common Stock, $.001 par value per share · 6,667 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 6,667 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 9 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 6,667 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 8 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 7 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Executive Officer and Director Ronen Luzon). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 17,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 6 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock, $.001 par value per share · 17,000 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 17,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 5 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 17,000 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 5,334 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 4 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Underlying: Common Stock, $.001 par value per share · 5,334 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 5,334 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 3 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 5,334 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 2 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:55 UTC |
Pardo BillyCPO & COO
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014426 · ownership.xml · derivative · entry 1 Pardo Billy · CIK 0001686858 · CPO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 6 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on May 1, 2020, one third of the total shares vests on May 1, 2021 and the remaining one third of the total shares vests on May 1, 2022. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 5 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on May 1, 2020, one third of the total shares vests on May 1, 2021 and the remaining one third of the total shares vests on May 1, 2022. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 4,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 4 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock, $.001 par value per share · 4,000 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 4,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 3 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 4,000 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 5,667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 2 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 Underlying: Common Stock, $.001 par value per share · 5,667 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:56 UTC |
Kles OrChief Financial Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 5,667 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014428 · ownership.xml · derivative · entry 1 Kles Or · CIK 0001686316 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 5,667 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 17,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 12 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,000 Underlying: Common Stock, $.001 par value per share · 17,000 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 17,000 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 11 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 17,000 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 5,334 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 10 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,334 Underlying: Common Stock, $.001 par value per share · 5,334 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 5,334 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 9 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 5,334 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 8 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 7 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. F5 · ownership.nature: Options acquired by Spouse (Chief Product Officer and Chief Operating Officer Billy Pardo). Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 33,334 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 6 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock, $.001 par value per share · 33,334 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 33,334 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 5 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 33,334 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F4 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on January 24, 2019, one third of the total shares vested on January 24, 2020 and the remaining one third of the total shares vests on January 24, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 6,667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 4 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock, $.001 par value per share · 6,667 shares Expires 2025-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 6,667 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 3 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 6,667 shares Expires 2024-05-29 F3 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 2 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2023-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 17:59 UTC |
Luzon RonenDirector · Chief Executive Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 10,000 | Not disclosed Strike: $18.15 | Not disclosed |
DisclosureSEC source: 0001213900-20-014434 · ownership.xml · derivative · entry 1 Luzon Ronen · CIK 0001686315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 10,000 shares Expires 2022-07-24 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of July 24, 2023. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 22:00 UTC |
Turchinsky IliaChief Technology Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 2,667 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014436 · ownership.xml · derivative · entry 4 Turchinsky Ilia · CIK 0001774527 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock, $.001 par value per share · 2,667 shares Expires 2024-09-06 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the option granted to the reporting person on April 15, 2019 having a lower exercise price of $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F3 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on July 1, 2019, one third of the total shares vests on July 1, 2020 and the remaining one third of the total shares vests on July 1, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 22:00 UTC |
Turchinsky IliaChief Technology Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 2,667 | Not disclosed Strike: $13.65 | Not disclosed |
DisclosureSEC source: 0001213900-20-014436 · ownership.xml · derivative · entry 3 Turchinsky Ilia · CIK 0001774527 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 2,667 shares Expires 2023-09-06 F4 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the option granted to the reporting person on April 15, 2019 having a lower exercise price of $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of September 6, 2024. All of the other terms of the option remained unchanged. F3 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, of which one third of the total shares vested on July 1, 2019, one third of the total shares vests on July 1, 2020 and the remaining one third of the total shares vests on July 1, 2021. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 22:00 UTC |
Turchinsky IliaChief Technology Officer
|
GrantOption to purchase Common Stock (right to buy) · Derivative | 1,004 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001213900-20-014436 · ownership.xml · derivative · entry 2 Turchinsky Ilia · CIK 0001774527 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004 Underlying: Common Stock, $.001 par value per share · 1,004 shares Expires 2025-05-29 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
| May 25, 2020 Filed Jun 8, 2020 22:00 UTC |
Turchinsky IliaChief Technology Officer
|
Disposition to issuerOption to purchase Common Stock (right to buy) · Derivative | 1,004 | Not disclosed Strike: $11.40 | Not disclosed |
DisclosureSEC source: 0001213900-20-014436 · ownership.xml · derivative · entry 1 Turchinsky Ilia · CIK 0001774527 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.001 par value per share · 1,004 shares Expires 2024-05-29 F2 · price: Effective May 25, 2020, the Board of Directors of the Company approved a unilateral option repricing and term extension, which resulted in the reduction of the exercise price to $1.04 per share, which is the closing price of the Company's common stock on May 22, 2020, and an expiration date of May 29, 2025. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Option grant under the My Size, Inc. 2017 Equity Incentive Plan, all of which have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.